IND Application filed for ML-016 for Advanced Solid Tumors with Lung and/or Liver Mets March 10, 2026
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors February 25, 2026
Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-gen T-cell Immunotherapy Platform February 25, 2026
MHRA and REC approved CTA for Ph 1 ZIMA-101 trial of ZI-MA4-1 in patients with advanced solid cancers February 25, 2026
FDA Clears IND Application for CS2009 (PD-1/VEGF/CTLA-4) to Advance into Ph 2 Clinical Trial February 25, 2026
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors February 17, 2026
CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in China February 17, 2026
First Patient Enrolled in Global Ph 1 Trial of AN9025 for Solid Tumors Harboring RAS Mutations February 17, 2026
FDA cleared IND application for NPX372 in B7-H7–expressing solid tumors, including lung adenocarcinoma, RCC, and pancreatic adenocarcinoma February 17, 2026
FDA clears IND application for Ph 1 study of GTB-5550 TriKE for Solid Tumors Expressing B7-H3 February 9, 2026
FDA clears IND application for Ph 1 study of N17350 in patients with advanced solid tumors February 9, 2026
Multiple Sites Activated for Ph 1b/2 Trial of AMXT 1501 and DFMO in Patients with solid tumors including Breast Cancer and Melanoma February 9, 2026
First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer February 9, 2026
AstraZeneca announced $15B investment in China through 2030 to expand medicines manufacturing and R&D February 1, 2026
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Gen Bi-and Multi-Functional Fusion Protein Pipeline February 1, 2026
Key Patent Filed and Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors Unveiled February 1, 2026
Eikon Therapeutics Secures $350.7M Series D to Advance Clinical-Stage Programs and Future Pipeline February 1, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
